By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Leukemia. According to news reporting from Doylestown, Pennsylvania, by NewsRx journalists, research stated, "The immunopathogenic mechanisms responsible for debilitating neurodegenerative and oncologic diseases associated with human T-cell leukemia virus type 1 (HTLV-1) are not fully understood. Quality of cytotoxic T lymphocytes (CTLs) is being increasingly associated with the outcome of persistent HTLV-1 infection."
The news correspondents obtained a quote from the research from Drexel University, "In this respect, a patient cohort (from HTLV-1 endemic region) consisting of seronegative controls (controls), asymptomatic carriers (ACs), and patients with adult T-cell leukemia (ATL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) was analyzed for CD8(+) T cells polyfunctionality in response to the viral antigen Tax. Compared to ACs, ATL and HAM/TSP patients had lower frequency and polyfunctionality of CTLs in response to Tax suggesting dysfunction of CD8(+) T cells in these individuals. As an underlying mechanism, programmed death-1 (PD-1) receptor was found to be highly unregulated in Tax-responsive as well as total CD8(+) T cells from ATL and HAM/TSP but not from ACs and directly correlated with the lack of polyfunctionality in these individuals. Further, PD-1 expression showed a direct whereas MIP-1 alpha expression had an indirect correlation with the proviral load providing new insights about the immunopathogenesis of HTLV-associated diseases. Additionally, we identified key cytokine signatures defining the immune activation status of clinical samples by the luminex assay."
According to the news reporters, the research concluded: "Collectively, our findings suggest that reconstitution of fully functional CTLs, stimulation of MIP-1 alpha expression, and/or blockade of the PD-1 pathway are potential approaches for immunotherapy / therapeutic vaccine against HTLV-mediated diseases."
For more information on this research see: Lack of Recall Response to Tax in ATL and HAM/TSP Patients But Not in Asymptomatic Carriers of Human T-cell Leukemia Virus Type 1. Journal of Clinical Immunology, 2013;33(7):1223-1239. Journal of Clinical Immunology can be contacted at: Springer, Plenum Publishers, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Journal of Clinical Immunology - www.springerlink.com/content/0271-9142/)
Our news journalists report that additional information may be obtained by contacting S.L. Manuel, Drexel University, Drexel Inst Biotechnol & Virol Res, Coll Med, Doylestown, PA 18902, United States. Additional authors for this research include M. Sehgal, J. Connolly, G. Makedonas, Z.K. Khan, J. Gardner, M.R. Betts and P. Jain (see also Leukemia).
Keywords for this news article include: Viruses, Oncology, Virology, Doylestown, Hematology, Immunology, CD Antigens, Pennsylvania, CD8 Antigens, Therapeutics, United States, Immunotherapy, Differentiation, Immunomodulation, Biological Factors, Human T-Cell Leukemia, Leukemia Gene Therapy, T-Lymphocyte Antigens, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC